Doug Morton, Ph.D., is presently a consultant in the life sciences arena, working with a variety of for-profit and non-profit organizations. From 2003-2006, he was CEO, Southwest Michigan Innovation Center, an incubator/accelerator located in Kalamazoo, MI that provides wet-laboratory space, access to venture funding and business services to emerging companies in the life sciences arena. Since 2006, he has continued his involvement with the Center as a member of its Managing Directors group. Doug spent the majority of his career in the pharmaceutical industry, joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn's merger with Pharmacia AB (in 1996), the consolidation of Pharmacia & Upjohn with Monsanto (in 2000), and Pharmacia's merger with Pfizer (2003) serving in a series of increasingly significant discovery research management positions. At the time of the Pfizer merger, he was Group Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation. In this position, he was responsible for technology acquisition and operations for worldwide Discovery Research throughout Pharmacia. Doug holds an A.B. degree (chemistry) from Kenyon College and a Ph.D. degree in Organic Chemistry from Columbia University. He completed postdoctoral studies in organic chemistry at Stanford University. Doug has served on the Board of Directors of TissueInformatics, Inc. from May 2003 until the closing of Paradigm Genetics' acquisition of the company in March 2004. He served as a member of the Board of Directors of Icoria, Inc. (formerly Paradigm Genetics, Inc.) since March 2004 until the acquisition of the Company by Clinical Data, Inc. in December 2005. He also served as Interim CEO of Icoria since April 2005 until the close of the acquisition with Clinical Data. Doug is a member of the Industrial Advisory Board of Cleveland Clinic Foundation Innovations. He is also a member of the Scientific Advisory Board and Management Committee of the Southwest Michigan First Life Science Fund and is also chairman of the Scientific Advisory Boards of Hopen Therapeutics and Metabolic Solutions Development. Doug is also a board member of NanoMed Pharmaceuticals, Inc., NephRx Corporation, TCH Pharmaceuticals, Inc., and Tolera Therapeutics, Inc.